WO2017131356A1 - Device for injecting drug in eyeball, having residual drug prevention capability and recharging function - Google Patents

Device for injecting drug in eyeball, having residual drug prevention capability and recharging function Download PDF

Info

Publication number
WO2017131356A1
WO2017131356A1 PCT/KR2017/000205 KR2017000205W WO2017131356A1 WO 2017131356 A1 WO2017131356 A1 WO 2017131356A1 KR 2017000205 W KR2017000205 W KR 2017000205W WO 2017131356 A1 WO2017131356 A1 WO 2017131356A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
injection device
intraocular
eye
eyeball
Prior art date
Application number
PCT/KR2017/000205
Other languages
French (fr)
Korean (ko)
Inventor
박철용
Original Assignee
동국대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동국대학교 산학협력단 filed Critical 동국대학교 산학협력단
Publication of WO2017131356A1 publication Critical patent/WO2017131356A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor

Definitions

  • the present invention relates to an intraocular drug injection device, and more particularly, to simplify the section in which injection is injected and delivered into the eye to effectively deliver the drug into the eye, thereby minimizing the residual rate of the drug in the device, Rechargeable intraocular drug injection device.
  • Some diseases and disorders of the posterior eyeball are threat to vision. Some examples are senile macular degeneration, choroidal neovascularization, retinopathy, retinitis, uveitis, macular edema, glaucoma, neuropathy.
  • Intravitreal administration of steroids is possible to treat eye diseases, but generally causes too serious side effects in ophthalmological applications. Therefore, topical administration, intravitreal administration and subtenon administration, are being studied. Although intravitreal administration may solve some problems associated with systemic administration, intravitreal administration of currently used ophthalmic compositions can cause ocular hypertension, steroidal glaucoma and posterior capsular cataract when administered steroids. Intravitreal administration of steroids also sometimes leads to postoperative complications. Subtenon administration is frequently used in clinical practice to reduce the tissue invasion potential and patient burden of intravitreal administration. Although steroid administration reduces the potential for tissue invasion compared to vitreous surgery, this method is still associated with postoperative complications.
  • intravitreal injection treatment which is a representative treatment for senile macular edema
  • a needle (30G)
  • a needle (30G)
  • Patients were afraid of injections, and more frequent phobias were observed with repeated injections.
  • the injection treatment is often repeated several dozen to more than 100 times, it is known that repeated injections increase the complications such as increased pain, vitreous hemorrhage, endophthalmitis, increased intraocular pressure, retinal detachment.
  • researchers are presenting a variety of implants for topical delivery of therapeutic agents to the eye.
  • the present invention has been made to solve the above problems, the present inventors have a drug injection device that can be easily recharged, provided with a drug moving unit that can minimize the residual amount of the drug to deliver the drug into the eye easily Invented.
  • a drug moving part 200 disposed below the drug chamber part 100 and providing a space for delivery of a drug into the eye through the sclera;
  • an intraocular drug injection device including a filter unit 300 is disposed between the drug chamber 100 and the drug moving unit 200 to remove the bacteria.
  • a drug moving part 200 disposed below the drug chamber part 100 and providing a space for delivery of a drug into the eye through the sclera;
  • an intraocular drug injection device comprising a filter unit 300 for removing the bacteria.
  • the intraocular drug injection device may further include a coating part 400 surrounding the outer circumference of the drug chamber part 100 to prevent exposure to the conjunctiva.
  • the drug chamber part 100 may include a drug injecting part 110 formed at an upper portion thereof and through which the drug injecting device may pass.
  • the drug moving part 200 may include a plurality of discharge parts 210 formed in the lower portion to discharge the drug into the eye.
  • the drug moving part 200 may include a fixing part 220 protruding from the outer circumference to fix the device.
  • the coating part 400 material is formed of a material selected from the group consisting of silicon, ceramic, polyetherurethane, abocoic acid polymerized with polydimethylsiloxane, and a copolymer of styrene and polyamine. Can be.
  • the intraocular drug injection device includes a rechargeable drug chamber part, a filter part for filtering bacteria, and a drug moving part, thereby delivering drugs into the eye through the device without the need for direct injection into the eye. More specifically, when the drug is injected into the drug chamber part, bacteria are filtered through the filter part that prevents bacterial infection from the outside, and the filtered drug may be delivered into the eye through the drug moving part. As such, the short-range connecting structure minimizes the amount of drug remaining in the device, so that the drug can be effectively delivered into the eye, thereby improving the treatment effect for diseases such as macular edema.
  • the intraocular drug injection device is expected to effectively prevent side effects such as phobias, bleeding, and increased intraocular pressure in patients with intravitreal injections performed during the treatment of senile macular edema.
  • FIG. 1 is a perspective view of an intraocular drug injection device 10 according to an embodiment of the present invention.
  • FIG. 2 is an exploded perspective view of the intraocular drug injection device 10 according to an embodiment of the present invention.
  • FIG 3 illustrates the internal state of the drug chamber unit 100 in the intraocular drug injection device 10 according to an embodiment of the present invention.
  • Figure 4 shows another embodiment of the intraocular drug injection device 10 according to an embodiment of the present invention.
  • Figure 5 shows the state of the coating unit 400 is wrapped around the outer circumference of the device implanted in the eye in the intraocular drug injection device 10 according to an embodiment of the present invention.
  • Figure 6 schematically shows the process of drug injection into the eye using the intraocular drug injection device 10 according to an embodiment of the present invention.
  • the intraocular drug injection device 10 includes a drug chamber 100, drug moving unit 200, and filter 300 It may be configured, and as shown in Figure 5, may be configured to further include a coating (400).
  • Intraocular drug injection device 10 is located under the conjunctiva of the ocular planar portion, through which the drug is injected into the drug chamber 100, the injected drug is a drug moving unit 200 Can be delivered into the eye.
  • the drug is injected in a short distance from the drug chamber unit 100 to the drug moving unit 200 is injected, it is possible to minimize the residual amount of the drug in the device.
  • it is expected to minimize the complications due to intravitreal intravitreal injection treatment in eye treatment administered over a long period of time.
  • the drug chamber part 100 is configured to carry a drug to be delivered, and the drug chamber part 100 is disposed under the conjunctiva of the ciliary plane, thereby injecting a drug from the outside using a drug injection device. Direct contact between the needle of the device and the eye can be prevented, and thus damage to the eye due to the needle can be prevented.
  • the drug chamber part 100 may be formed in a flat oval hemispherical shape in accordance with an arc of the eyeball surface in order to be disposed under the ciliary plane conjunctiva, but is not limited thereto.
  • the material used to form the drug chamber part 100 it is preferable to use a flexible silicone, parylene, acrylic material, and the like, and more preferably, silicon may be used, but is not limited thereto.
  • the drug storage capacity of the drug chamber unit 100 is preferably 0.1ml ⁇ 0.5ml, more preferably 0.3ml, but is not limited thereto.
  • the inside of the drug chamber part 100 may include an inclined surface for the flow of drugs. By including the inclined surface, when the drug contained in the drug chamber 100 moves to the drug moving unit 200 to be described later, it is possible to reduce the remaining drug as much as possible, by minimizing the remaining drug, new drug Injection of may be possible.
  • the drug injecting unit 110 is a portion in contact with the actual drug injecting device, and more specifically, a needle may inject the drug into the drug chamber 100 by penetrating the drug injecting unit 110.
  • the drug injecting unit 110 is formed on the drug chamber 100, preferably made of a flexible material to facilitate penetration. In this case, silicon or parylene may be used as the flexible material, but is not limited thereto. Since the drug injecting unit 110 is formed by a needle of the drug injecting device, the needle may penetrate and the drug may be injected into the drug chamber unit 100. On the other hand, when the injection of the drug is finished, and the drug injection mechanism is separated from the drug injection unit 110, the penetrated gap can be closed and close itself. In this case, the drug injection device may use a syringe, but is not limited thereto.
  • the drug moving unit 200 is disposed below the drug chamber unit 100 and passes through the sclera to deliver a drug injected from the drug chamber unit 100 into the eye.
  • the drug moving part 200 is preferably made of a hollow cylindrical shape, the lower portion in the form of a tip in order to penetrate the sclera directly, but is not limited thereto.
  • the drug moving part 200 is preferably made of a biocompatible material because the drug moving part 200 penetrates the sclera and makes direct contact with the eye tissue.
  • the biocompatible material may include, but is not limited to, parylene, polyether ether ketone (PEEK), polyethylene, polyimide, ethylene vinyl acetate, acrylic polymer, or a combination thereof.
  • the drug moving unit 200 is preferably able to select the length according to the thickness of the sclera of the patient.
  • the length of the drug moving part 200 may be 10 mm to 12 mm, but is not limited thereto.
  • Discharge unit 210 is a configuration for delivering the drug into the eye, as shown in Figure 2, may be formed in a plurality of the lower portion of the drug moving unit (200).
  • the drug moving part 200 may allow the drug to flow into the eyeball, and the intraocular fluid may also flow into the drug moving part 200 through the discharge part 210.
  • the drug and the intraocular fluid may be mixed in the drug moving unit 200, and can be discharged through diffusion into the eye, thereby minimizing the remaining drug in the device.
  • the intraocular drug injection device 10 according to an embodiment of the present invention has a fixing portion 220 for fixing the device to prevent the separation of the device to the drug moving unit 200 To prevent detachment of the device from the eye.
  • the fixing part 220 is configured to prevent the device from detaching from the eye in advance and to improve the insertion stability, as shown in FIG. 4, protruding from the outer periphery of the drug moving part 200. It may be, but is not limited to, it may be desirable to form a plurality.
  • the filter part 300 is disposed between the drug chamber part 100 and the drug moving part 200 to remove bacteria, and is introduced from the drug chamber part 100. Foreign substances such as bacteria other than the drug can be filtered, which can prevent eye infection caused by bacteria.
  • the filter part 300 is disposed between the drug chamber part 100 and the drug moving part 200 through which the drug injection device penetrates, and thus the filter part 300 by the drug injection device is damaged.
  • the drug chamber part 100 and the filter part 300 are arranged so that the arrangement of the drug chamber part 100 and the filter part 300 is not positioned on a straight line. Do.
  • the intraocular drug injection device 10 is positioned under the conjunctiva of the ciliary plane, and the exposed device is coated with the coating unit 400, which is This can prevent side effects caused by exposure to the device. In addition, it can be easily removed by removing the screw through a small incision when removing the device.
  • the coating unit 400 is configured to prevent side effects caused by the exposure of the device, as shown in Figure 5, to wrap the outer periphery of the drug chamber 100 to expose the exposure to the conjunctiva outside You can prevent it.
  • the coating unit 400 is preferably made of a biologically suitable material.
  • the biologically suitable material may be silicon, ceramic, polyetherurethane, abocoic acid polymerized with polydimethylsiloxane, or a copolymer of styrene and polyamine, but is not limited thereto.
  • the coating film 400 when injecting the drug into the drug chamber 100, it is preferably made of a transparent material for positioning of the device.
  • FIG. 6 schematically illustrates a process of injecting a drug into the eye using the intraocular drug injection device 10 according to an embodiment of the present invention.
  • the intraocular drug injection device 10 is placed under the ciliary plane conjunctiva, drug The chamber part 100 is exposed.
  • the needle of the drug injection device penetrates the drug injection unit 110 formed above the drug chamber unit 100 and starts to inject the drug to be delivered, the drug is injected into the drug chamber unit 100. Is injected and supported.
  • the needle of the drug injection device is separated from the drug chamber unit 100.
  • the penetrating gap of the drug injecting unit 110 may be closed by itself.
  • the supported drug causes the drug to move to the filter part 300 by the inclined surface of the drug chamber part 100, and to filter foreign substances such as bacteria from the filter part 300.
  • the filtered drug is immediately deployed to the drug moving part 200 and diffuses into the eye through the discharge part 210 and the intraocular fluid flows into the drug moving part 200 through the discharge part 210.
  • the drug and the intraocular fluid are mixed so that all drugs can eventually diffuse into the eye.
  • the intraocular drug injection device includes a rechargeable drug chamber part, a filter part for filtering bacteria, and a drug moving part, thereby delivering drugs into the eye through the device without the need for direct injection into the eye.
  • the short-range connecting structure minimizes the amount of drug remaining in the device, so that the drug can be effectively delivered into the eye, thereby improving the treatment effect for diseases such as macular edema.
  • the intraocular drug injection device is expected to effectively prevent side effects such as phobias, bleeding, and increased intraocular pressure in patients with intravitreal injections performed during the treatment of senile macular edema.

Abstract

The present invention relates to a device for injecting a drug in an eyeball, and more specifically, to a device for injecting a drug in an eyeball, the device comprising: a drug chamber part in which a drug may be repeatedly charged; a filter part enabling the prevention of bacterial infection; and a drug transfer part, and thus the device enables a drug to be efficiently transferred into an eyeball by minimizing the rate of residue of the drug by means of simplifying the structure by which the drug reaches the inside of the eyeball. As such, by means of the device for injecting a drug in an eyeball according to the present invention, a surgical procedure may be easily performed at a hospital, and a drug may be transferred into an eyeball while efficiently preventing side-effects associated with intravitreal injection treatment, etc., and thus the device is expected to be usefully employed for treating age-related macular edema, etc.

Description

약물 잔류 방지능 및 재충전 기능을 갖는 안구 내 약물 주입 장치Intraocular drug injection device with drug retention and recharge
본 발명은 안구 내 약물 주입 장치에 관한 것으로서, 보다 구체적으로는, 안구 내에 약물을 효과적으로 전달하기 위해 주사액이 주입되어 안구 내로 전달되는 구간을 단순화시켜 장치 내 약물의 잔존률을 최소화시키면서, 새로운 약물의 재충전이 가능한 안구 내 약물 주입 장치에 관한 것이다. The present invention relates to an intraocular drug injection device, and more particularly, to simplify the section in which injection is injected and delivered into the eye to effectively deliver the drug into the eye, thereby minimizing the residual rate of the drug in the device, Rechargeable intraocular drug injection device.
안구 후안부의 일부 질병 및 질환은 시력에 위협적이다. 노인성 황반변성, 맥락막 혈관신생, 망막병증, 망막염, 포도막염, 황반부종, 녹내장, 신경병증이 그 일부 예이다.Some diseases and disorders of the posterior eyeball are threat to vision. Some examples are senile macular degeneration, choroidal neovascularization, retinopathy, retinitis, uveitis, macular edema, glaucoma, neuropathy.
종래 황반부종의 치료로는 레이저 조사에 의한 광응고술, 유리체 수술, 전신 투여, 스테로이드의 유리체강내 투여 및 서브테논(sub-Tenon) 투여 등을 수행하였다. 레이저 조사에 의한 광응고술은 액체 누출이 일어나는 혈관을 막아서 황반의 부기를 감소시킨다. 그러나, 레이저 조사 시에 극도로 취약한 중심와(fovea)를 피하도록 주의하여야 한다. 중심와가 이 시술에 의해 상처를 받으면 중심 시야가 손상될 수 있다. 또한, 복수의 레이저 시술이 부기를 제거하기 위해 종종 필요하다. 유리체 수술은 레이저 시술이 비효과적인 경우에 적용하지만, 이 방법은 가끔 수술 후 합병증 문제를 야기하는 높은 조직 침습 가능성과 연관되어 있다. 또한, 스테로이드 투여가 유용하다고 보고되어 있다. 안질환을 치료하기 위해 스테로이드의 전신 투여가 가능하지만, 일반적으로 안과학적 용도에서 너무 심각한 부작용을 일으킨다. 그러므로 국소 투여인 유리체강내 투여 및 서브테논 투여가 연구되고 있다. 유리체강내 투여가 전신 투여와 연관된 일부 문제를 해결할 수는 있지만, 현재 사용되는 안과 조성물의 유리체강내 투여는, 스테로이드를 투여했을 때 고안압증, 스테로이드성 녹내장 및 후부 수정체피막하 백내장을 일으킬 수 있다. 또한 스테로이드의 유리체강내 투여는 때때로 수술 후 합병증을 유발한다. 서브테논 투여는 유리체강내 투여의 조직 침습 가능성과 환자 부담을 줄이기 위해 임상 실습에서 자주 사용한다. 유리체 수술과 비교하여 스테로이드 투여가 조직 침습 가능성을 줄이지만, 이 방법도 여전히 수술 후 합병증의 문제와 연관되어 있다.Conventional macular edema has been performed by photocoagulation by laser irradiation, vitreous surgery, systemic administration, intravitreal administration of steroids, and sub-Tenon administration. Photocoagulation by laser irradiation reduces swelling of the macula by blocking blood vessels from which fluid leaks. However, care should be taken to avoid extremely fragile fovea during laser irradiation. If the fovea is injured by this procedure, the central field of vision may be impaired. In addition, multiple laser procedures are often needed to remove swelling. Vitreous surgery is applied where laser surgery is ineffective, but this method is sometimes associated with a high tissue invasion potential that causes postoperative complications. It is also reported that steroid administration is useful. Systemic administration of steroids is possible to treat eye diseases, but generally causes too serious side effects in ophthalmological applications. Therefore, topical administration, intravitreal administration and subtenon administration, are being studied. Although intravitreal administration may solve some problems associated with systemic administration, intravitreal administration of currently used ophthalmic compositions can cause ocular hypertension, steroidal glaucoma and posterior capsular cataract when administered steroids. Intravitreal administration of steroids also sometimes leads to postoperative complications. Subtenon administration is frequently used in clinical practice to reduce the tissue invasion potential and patient burden of intravitreal administration. Although steroid administration reduces the potential for tissue invasion compared to vitreous surgery, this method is still associated with postoperative complications.
특히, 현재 노인성 황반부종의 대표적인 치료법인 유리체강 내 주사치료는 단클론항체제제인 황반부종 치료주사액을 매달 또는 수개월마다 약 0.5㎖을 가는 주사침 (30G)을 이용하여 눈속에 찔러 넣어야 한다. 환자들은 주사에 대한 공포심이 있으며, 주사를 반복해감에 따라 더 심한 공포증을 보이는 경향도 관찰되었다. 상기 주사 치료는 수십 번에서 100번이상 반복되는 경우가 많아서, 반복되는 주사는 통증의 증가, 유리체 출혈, 안내염, 안압상승, 망막박리등의 합병증을 증가시킨다고 알려져 있다. 따라서, 보다 나은 안구 치료법을 제공하기 위하여, 연구자들은 치료제를 안구로 국소 전달하기 위한 다양한 임플란트를 제시하고 있다. In particular, intravitreal injection treatment, which is a representative treatment for senile macular edema, should be injected into the eye using a needle (30G), which is about 0.5 ml every month or several months. Patients were afraid of injections, and more frequent phobias were observed with repeated injections. The injection treatment is often repeated several dozen to more than 100 times, it is known that repeated injections increase the complications such as increased pain, vitreous hemorrhage, endophthalmitis, increased intraocular pressure, retinal detachment. Thus, in order to provide better eye therapy, researchers are presenting a variety of implants for topical delivery of therapeutic agents to the eye.
따라서, 노인성 황반부종을 포함하는 안구 후안부 일부 질환을 치료하기 위해서, 안구내로의 효과적인 약물 전달을 위한 장치의 개발이 주요한 과제의 대상이 되고 있고, 이에 대한 연구가 이루어지고 있으나(한국공개특허 10-2006-0082792), 아직은 미비한 실정이다. Therefore, the development of a device for effective drug delivery into the eye for the treatment of some diseases of the posterior ocular eye, including senile macular edema, has been the subject of a major problem, but the research has been made (Korea Patent Publication 10) -2006-0082792), it is still inadequate.
본 발명은 상기와 같은 문제점을 해결하기 위해 안출된 것으로서, 본 발명자들은 재충전이 가능하며, 약물의 잔류량을 최소화 할 수 있는 약물 이동부를 구비하여 안구 내로 약물을 쉽게 전달할 수 있는 안구 내 약물 주입 장치를 발명하였다.The present invention has been made to solve the above problems, the present inventors have a drug injection device that can be easily recharged, provided with a drug moving unit that can minimize the residual amount of the drug to deliver the drug into the eye easily Invented.
이에, 본 발명의 목적은Thus, the object of the present invention
전달하고자 하는 약물이 담지되는 약물 챔버부(100);A drug chamber part 100 on which a drug to be delivered is carried;
상기 약물 챔버부(100) 하부에 배치되고, 공막을 관통하여 상기 안구 내로 약물의 전달을 위한 공간을 제공하는 약물 이동부(200); 및A drug moving part 200 disposed below the drug chamber part 100 and providing a space for delivery of a drug into the eye through the sclera; And
상기 약물 챔버부(100)와 약물 이동부(200) 사이에 배치되어 균을 제거하기 위한 필터부(300)를 포함하는, 안구 내 약물 주입 장치를 제공하는 것이다.It is to provide an intraocular drug injection device including a filter unit 300 is disposed between the drug chamber 100 and the drug moving unit 200 to remove the bacteria.
그러나 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problem, another task that is not mentioned will be clearly understood by those skilled in the art from the following description.
상기 목적을 달성하기 위하여, 본 발명은 In order to achieve the above object, the present invention
전달하고자 하는 약물이 담지되는 약물 챔버부(100);A drug chamber part 100 on which a drug to be delivered is carried;
상기 약물 챔버부(100) 하부에 배치되고, 공막을 관통하여 상기 안구 내로 약물의 전달을 위한 공간을 제공하는 약물 이동부(200); 및A drug moving part 200 disposed below the drug chamber part 100 and providing a space for delivery of a drug into the eye through the sclera; And
상기 약물 챔버부(100)와 약물 이동부(200) 사이에 배치되어 균을 제거하기 위한 필터부(300)를 포함하는 안구 내 약물 주입 장치를 제공한다.It is provided between the drug chamber 100 and the drug moving unit 200 provides an intraocular drug injection device comprising a filter unit 300 for removing the bacteria.
바람직하게는, 상기 안구 내 약물 주입 장치는, 상기 약물 챔버부(100) 외주연을 감싸 결막 외 노출을 방지하는 코팅부(400)를 더 포함할 수 있다.Preferably, the intraocular drug injection device may further include a coating part 400 surrounding the outer circumference of the drug chamber part 100 to prevent exposure to the conjunctiva.
바람직하게는, 상기 약물 챔버부(100)는, 상부에 형성되고, 약물 주입 기구가 관통될 수 있는 약물 주입부(110)를 포함할 수 있다.Preferably, the drug chamber part 100 may include a drug injecting part 110 formed at an upper portion thereof and through which the drug injecting device may pass.
바람직하게는, 상기 약물 이동부(200)는, 하부에 복수개로 형성되어 상기 약물을 안구 내로 배출하는 배출부(210)를 포함할 수 있다.Preferably, the drug moving part 200 may include a plurality of discharge parts 210 formed in the lower portion to discharge the drug into the eye.
바람직하게는, 상기 약물 이동부(200)는, 외주연에 돌출 형성되어 장치를 고정시키기 위한 고정부 (220)를 포함할 수 있다.Preferably, the drug moving part 200 may include a fixing part 220 protruding from the outer circumference to fix the device.
더욱 바람직하게는, 상기 코팅부(400) 소재는, 실리콘, 세라믹, 폴리에테르우레탄, 폴리다이메틸실록산을 중합한 아보코산, 및 스타이렌과 폴리아민의 공중합체로 이루어진 군으로부터 선택되는 물질로 형성될 수 있다.More preferably, the coating part 400 material is formed of a material selected from the group consisting of silicon, ceramic, polyetherurethane, abocoic acid polymerized with polydimethylsiloxane, and a copolymer of styrene and polyamine. Can be.
본 발명에 따른 안구 내 약물 주입 장치는 재충전이 가능한 약물 챔버부, 세균을 필터링하는 필터부, 및 약물 이동부를 포함함으로서, 안구에 직접 주사할 필요 없이 상기 장치를 통해 안구 내로 약물을 전달할 수 있다. 보다 구체적으로, 상기 약물 챔버부에 약물의 주입을 시작하면, 외부로부터의 세균 감염을 막는 상기 필터부를 통해 세균이 걸러지고, 필터링된 약물은 상기 약물 이동부를 통해 안구 내로 전달될 수 있다. 이와 같은, 단거리 연결구조는 장치 내 약물의 잔존량을 최소화시킴으로서, 안구 내로 약물이 효과적으로 전달될 수 있는바, 노인성 황반부종 등의 질환에 대한 치료 효과를 높일 수 있다.The intraocular drug injection device according to the present invention includes a rechargeable drug chamber part, a filter part for filtering bacteria, and a drug moving part, thereby delivering drugs into the eye through the device without the need for direct injection into the eye. More specifically, when the drug is injected into the drug chamber part, bacteria are filtered through the filter part that prevents bacterial infection from the outside, and the filtered drug may be delivered into the eye through the drug moving part. As such, the short-range connecting structure minimizes the amount of drug remaining in the device, so that the drug can be effectively delivered into the eye, thereby improving the treatment effect for diseases such as macular edema.
또한, 상기 안구 내 약물 주입 장치는 노인성 황반부종 등의 치료시 시행되는 유리체강 내 주사치료에 따른 환자의 공포증, 출혈, 및 안압상승 등과 같은 부작용을 효율적으로 예방할 수 있을 것으로 기대된다.In addition, the intraocular drug injection device is expected to effectively prevent side effects such as phobias, bleeding, and increased intraocular pressure in patients with intravitreal injections performed during the treatment of senile macular edema.
도 1은 본 발명의 일실시예에 따른 안구 내 약물 주입 장치(10)의 사시도이다.1 is a perspective view of an intraocular drug injection device 10 according to an embodiment of the present invention.
도 2는 본 발명의 일실시예에 따른 안구 내 약물 주입 장치(10)의 분해 사시도이다.2 is an exploded perspective view of the intraocular drug injection device 10 according to an embodiment of the present invention.
도 3은 본 발명의 일실시예에 따른 안구 내 약물 주입 장치(10)에서, 약물 챔버부(100)의 내부 상태를 나타낸 것이다.3 illustrates the internal state of the drug chamber unit 100 in the intraocular drug injection device 10 according to an embodiment of the present invention.
도 4는 본 발명의 일실시예에 따른 안구 내 약물 주입 장치(10)의 다른 양태를 나타낸 것이다.Figure 4 shows another embodiment of the intraocular drug injection device 10 according to an embodiment of the present invention.
도 5는 본 발명의 일실시예에 따른 안구 내 약물 주입 장치(10)에서, 안구에 이식한 장치 외주연을 감싸 코팅한 코팅부(400)의 상태를 나타낸 것이다.Figure 5 shows the state of the coating unit 400 is wrapped around the outer circumference of the device implanted in the eye in the intraocular drug injection device 10 according to an embodiment of the present invention.
도 6은 본 발명의 일실시예에 따른 안구 내 약물 주입 장치(10)를 사용하여 안구내로 약물이 주입되는 과정을 개략적으로 나타낸 것이다.Figure 6 schematically shows the process of drug injection into the eye using the intraocular drug injection device 10 according to an embodiment of the present invention.
이하, 첨부된 도면을 참조하여 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 본 발명을 용이하게 실시할 수 있도록 바람직한 실시예를 상세히 설명한다. 본 발명의 실시예를 설명하기 위한 도면에 개시된 형상, 크기, 비율, 각도, 개수 등은 예시적인 것이므로 본 발명이 도시된 사항에 한정되는 것은 아니다. 다만, 본 발명의 바람직한 실시예를 상세하게 설명함에 있어, 관련된 공지 기능 또는 구성에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우에는 그 상세한 설명을 생략한다. 또한, 유사한 기능 및 작용을 하는 부분에 대해서는 도면 전체에 걸쳐 동일한 부호를 사용한다.Hereinafter, exemplary embodiments of the present invention will be described in detail with reference to the accompanying drawings so that those skilled in the art may easily implement the present invention. Shapes, sizes, ratios, angles, numbers, and the like disclosed in the drawings for describing the embodiments of the present invention are exemplary, and the present invention is not limited to the illustrated items. However, in describing the preferred embodiment of the present invention in detail, if it is determined that the detailed description of the related known function or configuration may unnecessarily obscure the subject matter of the present invention, the detailed description thereof will be omitted. In addition, the same reference numerals are used throughout the drawings for parts having similar functions and functions.
덧붙여, 명세서 전체에서, 어떤 부분이 다른 부분과 ‘연결’되어 있다고 할 때, 이는 ‘직접적으로 연결’되어 있는 경우뿐만 아니라, 그 중간에 다른 소자를 사이에 두고 ‘간접적으로 연결’되어 있는 경우도 포함한다. 또한, 어떤 구성요소를 ‘포함’한다는 것은, 특별히 반대되는 기재가 없는 한 다른 구성요소를 제외하는 것이 아니라 다른 구성요소를 더 포함할 수 있다는 것을 의미한다.In addition, throughout the specification, when a part is 'connected' to another part, it is not only 'directly connected' but also 'indirectly connected' with another element in between. Include. In addition, "including" a certain component means that it may further include other components, except to exclude other components unless specifically stated otherwise.
도 1 및 도 2는 본 발명의 일실시예에 따른 안구 내 약물 주입 장치(10)의 사시도 및 분해 사시도를 도시한 것이다. 도 1 및 도 2에 도시된 바와 같이, 본 발명의 일실시예에 따른 안구 내 약물 주입 장치(10)는 약물 챔버부(100), 약물 이동부(200), 및 필터부(300)를 포함하여 구성될 수 있고, 도 5에 도시된 바와 같이, 코팅부(400)를 더 포함하여 구성될 수 있다.1 and 2 show a perspective view and an exploded perspective view of the intraocular drug injection device 10 according to an embodiment of the present invention. As shown in Figure 1 and 2, the intraocular drug injection device 10 according to an embodiment of the present invention includes a drug chamber 100, drug moving unit 200, and filter 300 It may be configured, and as shown in Figure 5, may be configured to further include a coating (400).
본 발명의 일실시예에 따른 안구 내 약물 주입 장치(10)는, 안구 모양체 평면부의 결막하에 위치되며, 이를 통해 약물이 약물 챔버부(100)로 주입되고, 주입된 약물은 약물 이동부(200)를 통해서, 안구 내로 전달될 수 있다. 이와 같은 구성을 채택함으로써, 약물이 주입되는 약물 챔버부(100)에서 약물 이동부(200)까지 단거리로 연결되어 있는바, 장치 내 약물의 잔류량을 최소화할 수 있다. 또한, 장시간에 걸쳐 투약하는 안구 치료를 함에 있어서, 기존에 실시되던 유리체강 내 주사치료에 따른 합병증을 최소화시킬 수 있을 것으로 기대된다.Intraocular drug injection device 10 according to an embodiment of the present invention, is located under the conjunctiva of the ocular planar portion, through which the drug is injected into the drug chamber 100, the injected drug is a drug moving unit 200 Can be delivered into the eye. By adopting such a configuration, the drug is injected in a short distance from the drug chamber unit 100 to the drug moving unit 200 is injected, it is possible to minimize the residual amount of the drug in the device. In addition, it is expected to minimize the complications due to intravitreal intravitreal injection treatment in eye treatment administered over a long period of time.
이하에서는, 본 발명의 일실시예에 따른 안구 내 약물 주입 장치(10)를 구성하는 각각의 구성요소에 대하여 상세히 설명하기로 한다.Hereinafter, each component constituting the intraocular drug injection device 10 according to an embodiment of the present invention will be described in detail.
약물 챔버부(100)는, 전달하고자 하는 약물이 담지 되는 구성으로서, 상기 약물 챔버부(100)는 모양체 평면부 결막하에 배치됨으로써, 외부로부터 약물 주입 기구를 이용하여 약물을 주입시킬 때, 약물 주입 기구의 니들(needle)과 안구와의 직접적인 접촉을 방지할 수 있는바, 니들(needle)에 의한 안구의 손상을 예방할 수 있다. 또한, 상기 약물 챔버부(100)는 모양체 평면부 결막하에 배치되기 위해서, 안구 표면의 원호에 맞추어 납작한 타원형의 반구 모양으로 형성될 수 있으나, 이제 제한되는 것은 아니다. 또한, 상기 약물 챔버부(100)를 형성하는데 사용되는 재료는 유연성이 있는 실리콘, 파릴렌, 아크릴 물질 등을 사용하는 것이 바람직하며, 더욱 바람직하게는 실리콘을 사용할 수 있으나, 이에 제한되는 것은 아니다. 더욱이, 상기 약물 챔버부(100)의 약물 저장용량은 0.1㎖ ~ 0.5㎖이 바람직하며, 더욱 바람직하게는 0.3㎖일 수 있으나, 이에 제한되는 것은 아니다. 또한, 도 3에 도시된 바와 같이, 상기 약물 챔버부(100)의 내부는 약물의 유동을 위한 경사면을 포함할 수 있다. 상기 경사면을 포함함으로서, 상기 약물 챔버부(100) 내부에 담지된 약물이 후술할 약물 이동부(200)로 이동할 때, 내부에 잔여 약물을 최대한 줄여줄 수 있고, 잔여 약물을 최소화시킴으로서, 새로운 약물의 주입이 가능할 수 있다. The drug chamber part 100 is configured to carry a drug to be delivered, and the drug chamber part 100 is disposed under the conjunctiva of the ciliary plane, thereby injecting a drug from the outside using a drug injection device. Direct contact between the needle of the device and the eye can be prevented, and thus damage to the eye due to the needle can be prevented. In addition, the drug chamber part 100 may be formed in a flat oval hemispherical shape in accordance with an arc of the eyeball surface in order to be disposed under the ciliary plane conjunctiva, but is not limited thereto. In addition, as the material used to form the drug chamber part 100, it is preferable to use a flexible silicone, parylene, acrylic material, and the like, and more preferably, silicon may be used, but is not limited thereto. Further, the drug storage capacity of the drug chamber unit 100 is preferably 0.1ml ~ 0.5ml, more preferably 0.3ml, but is not limited thereto. In addition, as shown in FIG. 3, the inside of the drug chamber part 100 may include an inclined surface for the flow of drugs. By including the inclined surface, when the drug contained in the drug chamber 100 moves to the drug moving unit 200 to be described later, it is possible to reduce the remaining drug as much as possible, by minimizing the remaining drug, new drug Injection of may be possible.
약물 주입부(110)는 실제 약물 주입 기구와 접촉하는 부분으로서, 보다 구체적으로는 니들이 상기 약물 주입부(110)를 관통함으로서, 상기 약물 챔버부(100)내에 약물을 주입할 수 있다. 이를 위해 상기 약물 주입부(110)는 상기 약물 챔버부(100) 상부에 형성되고, 관통이 용이하도록 유연한 소재로 이루어지는 것이 바람직하다. 이 때, 상기 유연한 소재로는 실리콘 또는 파릴렌 등을 사용할 수 있으나, 이에 제한되는 것은 아니다. 상기 약물 주입부(110)는 약물 주입 기구의 니들에 의해 틈이 생김으로서, 상기 니들이 관통되어 상기 약물 챔버부(100) 내로 약물이 주입될 수 있다. 반면에, 약물의 주입이 종료하여, 상기 약물 주입 기구를 상기 약물 주입부(110)로부터 분리하면, 관통되었던 틈이 메꿔지면서 스스로 폐쇄될 수 있다. 한편, 이 때, 상기 약물 주입 기구는 주사기를 사용할 수 있으나, 이에 제한되는 것은 아니다.The drug injecting unit 110 is a portion in contact with the actual drug injecting device, and more specifically, a needle may inject the drug into the drug chamber 100 by penetrating the drug injecting unit 110. To this end, the drug injecting unit 110 is formed on the drug chamber 100, preferably made of a flexible material to facilitate penetration. In this case, silicon or parylene may be used as the flexible material, but is not limited thereto. Since the drug injecting unit 110 is formed by a needle of the drug injecting device, the needle may penetrate and the drug may be injected into the drug chamber unit 100. On the other hand, when the injection of the drug is finished, and the drug injection mechanism is separated from the drug injection unit 110, the penetrated gap can be closed and close itself. In this case, the drug injection device may use a syringe, but is not limited thereto.
약물 이동부(200)는 도 1 및 도 2에 도시된 바와 같이, 상기 약물 챔버부(100) 하부에 배치되고, 공막을 관통하여 상기 약물 챔버부(100)로부터 주입된 약물을 안구 내로 전달하기 위한 공간을 제공할 수 있다. 이 때, 상기 약물 이동부(200)는 직접 공막을 관통시키기 위하여, 바람직하게는 중공형의 원통형으로 이루어지되, 하부는 팁의 형태로 이루어질 수 있으나, 이에 제한되는 것은 아니다. 또한, 상기 약물 이동부(200)는 공막을 관통하여 안구조직과 직접 접촉하기 때문에 생체적합성 물질로 구성되는 것이 바람직하다. 상기 생체적합성 물질로는 파릴렌, 폴리에테르에테르케톤(PEEK), 폴리에틸렌, 폴리이미드, 에틸렌 비닐 아세테이트, 아크릴성 폴리머, 또는 이들의 배합물 등을 사용할 수 있으나, 이에 제한되는 것은 아니다. 또한, 상기 약물 이동부(200)는 환자의 공막 두께에 따라 길이를 선택할 수 있는 것이 바람직하다. 예컨대, 상기 약물 이동부(200)의 길이는 10 ㎜ ~ 12 ㎜ 일 수 있으나, 이에 제한되는 것은 아니다.As illustrated in FIGS. 1 and 2, the drug moving unit 200 is disposed below the drug chamber unit 100 and passes through the sclera to deliver a drug injected from the drug chamber unit 100 into the eye. Can provide space for At this time, the drug moving part 200 is preferably made of a hollow cylindrical shape, the lower portion in the form of a tip in order to penetrate the sclera directly, but is not limited thereto. In addition, the drug moving part 200 is preferably made of a biocompatible material because the drug moving part 200 penetrates the sclera and makes direct contact with the eye tissue. The biocompatible material may include, but is not limited to, parylene, polyether ether ketone (PEEK), polyethylene, polyimide, ethylene vinyl acetate, acrylic polymer, or a combination thereof. In addition, the drug moving unit 200 is preferably able to select the length according to the thickness of the sclera of the patient. For example, the length of the drug moving part 200 may be 10 mm to 12 mm, but is not limited thereto.
배출부(210)는 약물을 안구 내로 전달하기 위한 구성으로서, 도 2에 도시된 바와 같이, 상기 약물 이동부(200) 하부에 복수개로 형성될 수 있다. 이에, 상기 약물 이동부(200)에서 약물이 안구 내로 흘러나가게 할 수 있으며, 또한, 안구내액은 상기 배출부(210)을 통해서, 상기 약물 이동부(200) 내부로 흘러 들어올 수도 있다. 이를 통해, 약물과 안구내액이 상기 약물 이동부(200) 내에서 혼합될 수 있으며, 안구내로 확산을 통해 배출될 수 있는바, 장치 내에 잔여 약물을 최소화시킬 수 있다. Discharge unit 210 is a configuration for delivering the drug into the eye, as shown in Figure 2, may be formed in a plurality of the lower portion of the drug moving unit (200). Thus, the drug moving part 200 may allow the drug to flow into the eyeball, and the intraocular fluid may also flow into the drug moving part 200 through the discharge part 210. Through this, the drug and the intraocular fluid may be mixed in the drug moving unit 200, and can be discharged through diffusion into the eye, thereby minimizing the remaining drug in the device.
한편, 본 발명에 따른 안구 내 약물 주입 장치(10)를 안구 내에 장착한 뒤, 안구의 움직임이나, 안구내 환경 변화 등에 따라서, 장치가 고정되지 않아 외부로 이탈하는 문제가 발생하게 되었다. 이와 같은 문제를 해결하기 위해서, 본 발명의 일실시예에 따른 안구 내 약물 주입 장치(10)는 장치의 이탈을 방지하여 장치를 고정시키기 위한 고정부(220)를 상기 약물 이동부(200)에 배치하여, 안구로부터 장치의 이탈을 방지하였다.On the other hand, after mounting the intraocular drug injection device 10 according to the present invention in the eyeball, the device is not fixed due to the movement of the eye, changes in the environment of the eyeball, etc., the problem of leaving the outside occurs. In order to solve this problem, the intraocular drug injection device 10 according to an embodiment of the present invention has a fixing portion 220 for fixing the device to prevent the separation of the device to the drug moving unit 200 To prevent detachment of the device from the eye.
보다 구체적으로, 고정부(220)는 장치를 안구로부터 미연에 이탈을 방지하고, 삽입 안정성을 증진시키기 위한 구성으로서, 도 4에 도시된 바와 같이, 상기 약물 이동부(200) 외주연에 돌출 형성될 수 있으며, 제한되지는 않으나 복수개로 형성되는 것이 바람직할 수 있다.More specifically, the fixing part 220 is configured to prevent the device from detaching from the eye in advance and to improve the insertion stability, as shown in FIG. 4, protruding from the outer periphery of the drug moving part 200. It may be, but is not limited to, it may be desirable to form a plurality.
필터부(300)는 도 2에 도시된 바와 같이, 상기 약물 챔버부(100)와 약물 이동부(200) 사이에 배치되어 균을 제거하기 위한 구성으로서, 상기 약물 챔버부(100)에서 도입되는 약물 외의 세균 등의 이물질을 필터링할 수 있는바, 세균으로 인한 안구의 감염을 예방할 수 있다.As shown in FIG. 2, the filter part 300 is disposed between the drug chamber part 100 and the drug moving part 200 to remove bacteria, and is introduced from the drug chamber part 100. Foreign substances such as bacteria other than the drug can be filtered, which can prevent eye infection caused by bacteria.
전술한 바와 같이, 상기 필터부(300)는, 약물 주입 기구가 관통되는 약물 챔버부(100) 및 약물 이동부(200) 사이에 배치되기 때문에 약물 주입 기구에 의한 상기 필터부(300)가 손상되는 문제가 발생할 수 있어, 이와 같은 문제를 해결하기 위해서, 도 4에 도시된 바와 같이, 상기 약물 챔버부(100) 및 필터부(300)의 배치가 직선상에 위치되지 않도록 배치되는 것이 가장 바람직하다.As described above, the filter part 300 is disposed between the drug chamber part 100 and the drug moving part 200 through which the drug injection device penetrates, and thus the filter part 300 by the drug injection device is damaged. In order to solve this problem, as shown in FIG. 4, it is most preferable that the drug chamber part 100 and the filter part 300 are arranged so that the arrangement of the drug chamber part 100 and the filter part 300 is not positioned on a straight line. Do.
한편, 안구내로 약물을 전달하는 기존 장치들의 경우, 안구에 이식시킬 때, 장치의 노출을 막기 위해, 장치를 안구의 상당히 뒷부분에 위치시켰다. 이로 인해, 추가 약물 투입의 어려움이 있었으며, 장치를 삽입 및 제거시 복잡한 수술이 진행되기 마련이었다. 따라서, 이러한 문제점을 해결하기 위해 본 발명의 일실시예에 따른 안구 내 약물 주입 장치(10)는 모양체 평면부의 결막 하에 위치시키고, 노출되어 있는 장치를 코팅부(400)로 코팅을 하였는바, 이를 통해 장치의 노출에 의해 발생되는 부작용을 막을 수 있다. 또한, 장치의 제거시 작은 절개창을 통하여 나사못을 뽑는 방식으로 손쉽게 제거될 수 있다.On the other hand, with existing devices that deliver drugs into the eye, when implanted into the eye, the device was placed at the very back of the eye to prevent exposure of the device. Due to this, there was a difficulty in adding additional drugs, and complex surgery was performed when the device was inserted and removed. Therefore, in order to solve this problem, the intraocular drug injection device 10 according to an embodiment of the present invention is positioned under the conjunctiva of the ciliary plane, and the exposed device is coated with the coating unit 400, which is This can prevent side effects caused by exposure to the device. In addition, it can be easily removed by removing the screw through a small incision when removing the device.
보다 구체적으로, 코팅부(400)는 장치의 노출에 의해 발생되는 부작용을 막기 위한 구성으로서, 도 5에 도시된 바와 같이, 상기 약물 챔버부(100)의 외주연을 감싸게 하여 결막 외로의 노출을 방지할 수 있다. 상기 코팅부(400)는 생물학적으로 적합한 물질로 구성되는 것이 바람직하다. 상기 생물학적으로 적합한 물질로는 실리콘, 세라믹, 폴리에테르우레탄, 폴리다이메틸실록산을 중합한 아보코산, 또는 스타이렌과 폴리아민의 공중합체 등을 사용할 수 있으나, 이에 제한되는 것은 아니다. 또한, 상기 코팅막(400)은 상기 약물 챔버부(100)로 약물을 주입할 때, 장치의 위치 확인을 위해서 투명한 물질로 구성되는 것이 바람직하다.More specifically, the coating unit 400 is configured to prevent side effects caused by the exposure of the device, as shown in Figure 5, to wrap the outer periphery of the drug chamber 100 to expose the exposure to the conjunctiva outside You can prevent it. The coating unit 400 is preferably made of a biologically suitable material. The biologically suitable material may be silicon, ceramic, polyetherurethane, abocoic acid polymerized with polydimethylsiloxane, or a copolymer of styrene and polyamine, but is not limited thereto. In addition, the coating film 400, when injecting the drug into the drug chamber 100, it is preferably made of a transparent material for positioning of the device.
도 6은 본 발명의 일실시예에 따른 안구 내 약물 주입 장치(10)를 사용하여 안구내로 약물이 주입되는 과정을 개략적으로 도시한 것이다. 도 6에 도시된 바와 같이, 본 발명의 일실시예에 따른 안구 내 약물 주입 장치(10)를 사용하기 위해서, 먼저, 상기 안구 내 약물 주입 장치(10)를 모양체 평면부 결막하에 배치시켜, 약물 챔버부(100)를 노출시킨다. 이로 인해, 약물 주입 기구를 통해 약물을 주입시킬 때, 약물 주입 기구의 니들(needle)이 안구와 접촉하여 안구를 손상시키는 것을 예방할 수 있다. 이 후, 상기 약물 주입 기구의 니들을 상기 약물 챔버부(100) 상부에 형성되어 있는 약물 주입부(110)에 관통시켜 전달하고자 하는 약물의 주입을 시작하면, 상기 약물 챔버부(100) 내로 약물이 주입되어 담지 되게 된다. 약물의 주입이 끝나면, 약물 주입 기구의 니들을 상기 약물 챔버부(100)에서 분리를 시킨다. 이 때, 상기 약물 주입부(110)의 관통되었던 틈이 메꿔지면서 스스로 폐쇄될 수 있다. 담지된 약물은 상기 약물 챔버부(100) 내부의 경사면에 의해서 약물이 필터부(300)로 이동하게 되고, 상기 필터부(300)에서 세균 등의 이물질을 걸러내게 한다. 필터링된 약물은 곧바로 약물 이동부(200)로 전개되고, 배출부(210)를 통해 안구 내로 확산이 되는 동시에 안구내액이 상기 배출부(210)을 통해 상기 약물 이동부(200) 내부로 흘러 들어올 수 있다. 이 과정에서 약물과 안구내액이 혼합되기 때문에 결국 모든 약물이 안구내로 확산될 수 있다. 이를 통해, 장치 내의 잔여 약물을 최소화 시킬 수 있으며, 또한, 잔여 약물의 최소화는 원하는 주입량과 실제 안구 내로의 도달량의 차이를 최소화 할 수 있는바, 안구내부로 약물을 효과적으로 주입할 수 있다. 또한, 장치 내의 잔존하는 약물을 최소화할 수 있기 때문에, 새로운 약물의 주입이 되어도, 약물간의 혼합으로 인한 변성을 예방할 수 있어, 약물의 재충전이 가능하다. 이를 통해, 여러 안구 후안부 질환을 갖는 환자에게 이식 후 여러 치료제를 사용할 수 있게 하여, 치료를 효과적으로 진행할 수 있으며, 또한, 장기간 치료가 가능하다.6 schematically illustrates a process of injecting a drug into the eye using the intraocular drug injection device 10 according to an embodiment of the present invention. As shown in Figure 6, in order to use the intraocular drug injection device 10 according to an embodiment of the present invention, first, the intraocular drug injection device 10 is placed under the ciliary plane conjunctiva, drug The chamber part 100 is exposed. Thus, when injecting the drug through the drug injection device, it is possible to prevent the needle of the drug injection device from coming into contact with the eye and damaging the eye. Thereafter, when the needle of the drug injection device penetrates the drug injection unit 110 formed above the drug chamber unit 100 and starts to inject the drug to be delivered, the drug is injected into the drug chamber unit 100. Is injected and supported. After the injection of the drug, the needle of the drug injection device is separated from the drug chamber unit 100. At this time, the penetrating gap of the drug injecting unit 110 may be closed by itself. The supported drug causes the drug to move to the filter part 300 by the inclined surface of the drug chamber part 100, and to filter foreign substances such as bacteria from the filter part 300. The filtered drug is immediately deployed to the drug moving part 200 and diffuses into the eye through the discharge part 210 and the intraocular fluid flows into the drug moving part 200 through the discharge part 210. Can be. During this process, the drug and the intraocular fluid are mixed so that all drugs can eventually diffuse into the eye. Through this, it is possible to minimize the residual drug in the device, and furthermore, minimizing the residual drug can minimize the difference between the desired injection amount and the amount reached into the actual eye, which can effectively inject the drug into the eye. In addition, since the drug remaining in the device can be minimized, even when a new drug is injected, degeneration due to mixing between drugs can be prevented, and the drug can be refilled. Through this, it is possible to use various therapeutic agents after transplantation to patients with various posterior ocular diseases, thereby effectively proceeding the treatment and also allowing long-term treatment.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다.The foregoing description of the present invention is intended for illustration, and it will be understood by those skilled in the art that the present invention may be easily modified in other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments described above are exemplary in all respects and not restrictive.
본 발명에 따른 안구 내 약물 주입 장치는 재충전이 가능한 약물 챔버부, 세균을 필터링하는 필터부, 및 약물 이동부를 포함함으로서, 안구에 직접 주사할 필요 없이 상기 장치를 통해 안구 내로 약물을 전달할 수 있다. 이와 같은, 단거리 연결구조는 장치 내 약물의 잔존량을 최소화시킴으로서, 안구 내로 약물이 효과적으로 전달될 수 있는바, 노인성 황반부종 등의 질환에 대한 치료 효과를 높일 수 있다.The intraocular drug injection device according to the present invention includes a rechargeable drug chamber part, a filter part for filtering bacteria, and a drug moving part, thereby delivering drugs into the eye through the device without the need for direct injection into the eye. As such, the short-range connecting structure minimizes the amount of drug remaining in the device, so that the drug can be effectively delivered into the eye, thereby improving the treatment effect for diseases such as macular edema.
또한, 상기 안구 내 약물 주입 장치는 노인성 황반부종 등의 치료시 시행되는 유리체강 내 주사치료에 따른 환자의 공포증, 출혈, 및 안압상승 등과 같은 부작용을 효율적으로 예방할 수 있을 것으로 기대된다.In addition, the intraocular drug injection device is expected to effectively prevent side effects such as phobias, bleeding, and increased intraocular pressure in patients with intravitreal injections performed during the treatment of senile macular edema.

Claims (6)

  1. 안구 내 약물 주입 장치에 있어서,In the intraocular drug injection device,
    전달하고자 하는 약물이 담지되는 약물 챔버부(100);A drug chamber part 100 on which a drug to be delivered is carried;
    상기 약물 챔버부(100) 하부에 배치되고, 공막을 관통하여 상기 안구 내로 약물의 전달을 위한 공간을 제공하는 약물 이동부(200); 및A drug moving part 200 disposed below the drug chamber part 100 and providing a space for delivery of a drug into the eye through the sclera; And
    상기 약물 챔버부(100)와 약물 이동부(200) 사이에 배치되어 균을 제거하기 위한 필터부(300)를 포함하는, 안구 내 약물 주입 장치.An intraocular drug injection device including a filter unit 300 disposed between the drug chamber unit 100 and the drug moving unit 200 to remove bacteria.
  2. 제1항에 있어서, 상기 안구 내 약물 주입 장치는, 상기 약물 챔버부(100) 외주연을 감싸 결막 외 노출을 방지하는 코팅부(400)를 더 포함하는 것을 특징으로 하는, 안구 내 약물 주입 장치.According to claim 1, wherein the intraocular drug injection device, the intraocular drug injection device, characterized in that it further comprises a coating 400 for wrapping the outer periphery of the drug chamber unit 100 to prevent extraconjunctival exposure. .
  3. 제1항에 있어서, 상기 약물 챔버부(100)는, 상부에 형성되고, 약물 주입 기구가 관통될 수 있는 약물 주입부(110)를 포함하는 것을 특징으로 하는, 안구 내 약물 주입 장치.The intraocular drug injection device of claim 1, wherein the drug chamber part (100) includes a drug injection part (110) formed thereon and through which the drug injection device can pass.
  4. 제1항에 있어서, 상기 약물 이동부(200)는, 하부에 복수개로 형성되어 상기 약물을 안구 내로 배출하는 배출부(210)를 포함하는 것을 특징으로 하는, 안구 내 약물 주입 장치.The intraocular drug injection device according to claim 1, wherein the drug moving part (200) comprises a plurality of discharge parts (210) formed at a lower part and discharging the drug into the eye.
  5. 제1항에 있어서, 상기 약물 이동부(200)는, 외주연에 돌출 형성되어 장치를 고정시키기 위한 고정부(220)를 포함하는 것을 특징으로 하는, 안구 내 약물 주입 장치.The intraocular drug injection device according to claim 1, wherein the drug moving part (200) includes a fixing part (220) for protruding the outer circumference to fix the device.
  6. 제2항에 있어서, 상기 코팅부(400) 소재는, 실리콘, 세라믹, 폴리에테르우레탄, 폴리다이메틸실록산을 중합한 아보코산, 및 스타이렌과 폴리아민의 공중합체로 이루어진 군으로부터 선택되는 물질로 형성되는 것을 특징으로 하는, 안구 내 약물 주입 장치.The material of claim 2, wherein the coating part 400 is made of a material selected from the group consisting of silicon, ceramic, polyetherurethane, abocoic acid polymerized with polydimethylsiloxane, and a copolymer of styrene and polyamine. An intraocular drug injection device, characterized in that it is formed.
PCT/KR2017/000205 2016-01-28 2017-01-06 Device for injecting drug in eyeball, having residual drug prevention capability and recharging function WO2017131356A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0010963 2016-01-28
KR1020160010963A KR101750651B1 (en) 2016-01-28 2016-01-28 Intraocular drug injection device having a drug residue prevention and a refill function

Publications (1)

Publication Number Publication Date
WO2017131356A1 true WO2017131356A1 (en) 2017-08-03

Family

ID=59283503

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/000205 WO2017131356A1 (en) 2016-01-28 2017-01-06 Device for injecting drug in eyeball, having residual drug prevention capability and recharging function

Country Status (2)

Country Link
KR (1) KR101750651B1 (en)
WO (1) WO2017131356A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100313268B1 (en) * 1993-02-26 2002-11-22 산텐 세이야꾸 가부시키가이샤 Biodegradable Scleral Plug
KR20070035529A (en) * 2004-06-01 2007-03-30 벡톤 디킨슨 앤드 컴퍼니 Ocular implant and methods for making and using same
KR20110119681A (en) * 2009-01-02 2011-11-02 알콘 리서치, 리미티드 In-situ refillable ophthalmic implant
US20140243795A1 (en) * 2001-06-12 2014-08-28 Johns Hopkins University School Of Medicine Reservoir Device for Intraocular Drug Delivery
US20140296800A1 (en) * 2013-03-28 2014-10-02 Forsight Vision4, Inc. Ophthalmic Implant for Delivering Therapeutic Substances

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100313268B1 (en) * 1993-02-26 2002-11-22 산텐 세이야꾸 가부시키가이샤 Biodegradable Scleral Plug
US20140243795A1 (en) * 2001-06-12 2014-08-28 Johns Hopkins University School Of Medicine Reservoir Device for Intraocular Drug Delivery
KR20070035529A (en) * 2004-06-01 2007-03-30 벡톤 디킨슨 앤드 컴퍼니 Ocular implant and methods for making and using same
KR20110119681A (en) * 2009-01-02 2011-11-02 알콘 리서치, 리미티드 In-situ refillable ophthalmic implant
US20140296800A1 (en) * 2013-03-28 2014-10-02 Forsight Vision4, Inc. Ophthalmic Implant for Delivering Therapeutic Substances

Also Published As

Publication number Publication date
KR101750651B1 (en) 2017-06-23

Similar Documents

Publication Publication Date Title
JP4261343B2 (en) Ophthalmic drug administration device
AU2002319606B2 (en) Ophthalmic drug delivery device
JP4837861B2 (en) Drug delivery formulation
RU2099031C1 (en) System for delivering medical preparations
JP5896966B2 (en) Reservoir device for intraocular drug delivery
JP4685311B2 (en) Ophthalmic drug delivery device
CA2498489C (en) Method for subretinal administration of therapeutics including steroids;method for localizing pharmacodynamic action at the choroid and the retina; and related methods for treatment and/or prevention of retinal diseases
AU2002319606A1 (en) Ophthalmic drug delivery device
AU2002319596A1 (en) Ophthalmic drug delivery device
TW201936135A (en) Fluid exchange apparatus for expandable port delivery system and methods of use
US20080140024A1 (en) Drug delivery device
WO2017131356A1 (en) Device for injecting drug in eyeball, having residual drug prevention capability and recharging function
CN115919539A (en) Injector for delivering implants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17744478

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17744478

Country of ref document: EP

Kind code of ref document: A1